Steven Cohen Lexicon Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,230,050 shares of LXRX stock, worth $873,335. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,230,050

Previous 4,121,191 70.15%

Holding current value

$873,335

Previous $6.92 Million 72.11%

% of portfolio

0.01%

Previous 0.02%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.51 - $2.39 $4.37 Million - $6.91 Million	-2,891,141 Reduced 70.15%	1,230,050 $1.93 Million
Q2 2024 Aug 14, 2024	BUY	$1.54 - $2.28 $5.45 Million - $8.06 Million	3,536,805 Added 605.22%	4,121,191 $6.92 Million
Q1 2024 May 15, 2024	BUY	$1.3 - $3.58 $759,701 - $2.09 Million	584,386 New	584,386 $1.4 Million
Q1 2023 May 15, 2023	SELL	$1.99 - $2.68 $1.65 Million - $2.22 Million	-827,764 Reduced 61.58%	516,367 $1.25 Million
Q4 2022 Feb 14, 2023	SELL	$1.8 - $2.56 $4.08 Million - $5.81 Million	-2,269,369 Reduced 62.8%	1,344,131 $2.57 Million
Q3 2022 Nov 14, 2022	BUY	$1.94 - $3.43 $7.01 Million - $12.4 Million	3,613,500 New	3,613,500 $8.67 Million
Q4 2019 Feb 14, 2020	SELL	$3.16 - $5.15 $1.67 Million - $2.72 Million	-528,100 Closed	0 $0
Q3 2019 Nov 15, 2019	BUY	$1.2 - $6.66 $633,720 - $3.52 Million	528,100 New	528,100 $1.59 Million

Others Institutions Holding LXRX

# of Institutions

141

Shares Held

238M

Call Options Held

459K

Put Options Held

133K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $134M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account